Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

12.09.24	Lilly expands manufacturing footprint in Ireland with $1.8 billion investment (EN, Eli Lilly)
11.09.24	Lilly's Weekly Efsitora Alfa Insulin Delivers A1C Reduction Consistent With Daily Insulin (RTTNews)
10.09.24	With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes (EN, Eli Lilly)
10.09.24	Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes (EN, Eli Lilly)
09.09.24	Lilly Names Lucas Montarce EVP And CFO With Immediate Effect (RTTNews)
09.09.24	Lilly appoints Lucas Montarce as executive vice president and chief financial officer (EN, Eli Lilly)
05.09.24	Lilly's QWINT-1, QWINT-3 Phase 3 Studies In Once Weekly Insulin Efsitora Alfa Meet Primary Goals (RTTNews)
05.09.24	In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin (EN, Eli Lilly)
05.09.24	QIAGEN, Lilly To Develop QIAstat-Dx IVD Panel For Early Alzheimer's Disease Risk Identification (RTTNews)
04.09.24	Lilly And EVA Pharma To Expand Access To Baricitinib In Low-to Middle-income Countries In Africa (RTTNews)
04.09.24	Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries (EN, Eli Lilly)
27.08.24	Lilly Releases 2.5 Mg And 5 Mg Vials Of Obesity Drug Zepbound (RTTNews)
27.08.24	Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity (EN, Eli Lilly)
22.08.24	Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference (EN, Eli Lilly)
20.08.24	Eli Lilly: Tirzepatide Lowers Risk Of Developing Type 2 Diabetes By 94% In 3-yr Study (RTTNews)
20.08.24	Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight (EN, Eli Lilly)
16.08.24	Lilly announces retirement of Marschall S. Runge from its Board of Directors (EN, Eli Lilly)
16.08.24	Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease (EN, Eli Lilly)
13.08.24	Lilly opens state-of-the-art research and development center in the Boston Seaport (EN, Eli Lilly)
08.08.24	Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook (RTTNews)
08.08.24	Eli Lilly Again Boosts FY24 Outlook - Update (RTTNews)
08.08.24	Eli Lilly And Co. Q2 Profit Increases, Beats Estimates (RTTNews)
08.08.24	Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion (EN, Eli Lilly)
04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
01.08.24	Lilly Reports Positive Topline Results From SUMMIT Phase 3 Study Of Tirzepatide (RTTNews)
01.08.24	Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity (EN, Eli Lilly)
25.07.24	Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement (EN, Eli Lilly)
17.07.24	Aclaris Sells OLUMIANT Royalties & Milestones To OMERS For Up To $31.5 Mln; Stock Up In After-hours (RTTNews)
08.07.24	Lilly To Acquire Morphic In Approx. $3.2 Bln Deal - Quick Facts (RTTNews)
08.07.24	Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease (EN, Eli Lilly)
03.07.24	FDA Approves Lilly's Kisunla To Treat Early Symptomatic Alzheimer's Disease (RTTNews)
02.07.24	Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease (EN, Eli Lilly)
25.06.24	Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials (RTTNews)
25.06.24	Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria (EN, Eli Lilly)
24.06.24	Lilly Declares Third-Quarter 2024 Dividend (EN, Eli Lilly)
21.06.24	Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution (EN, Eli Lilly)
20.06.24	Lilly Warns Patients About Counterfeit and Compounded Medicines Releases Open Letter and Takes Further Legal Action Against Counterfeit, Fake, Unsafe, and Untested Products (EN, Eli Lilly)
20.06.24	An Open Letter From Eli Lilly and Company Regarding Certain Practices Related to Mounjaro® and Zepbound® (EN, Eli Lilly)
08.06.24	Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks (EN, Eli Lilly)
05.06.24	Eli Lilly CFO Anat Ashkenazi Resigns (RTTNews)
05.06.24	Lilly announces departure of Anat Ashkenazi, chief financial officer (EN, Eli Lilly)
04.06.24	Melissa Seymour to join Lilly as executive vice president of Global Quality (EN, Eli Lilly)
01.06.24	Lilly Announces Updated Data From Phase 1/2 Study Of Olomorasib In Advanced Solid Tumors (RTTNews)
01.06.24	Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting (EN, Eli Lilly)
30.05.24	Biotech Stocks Facing FDA Decision In June 2024 (RTTNews)
29.05.24	Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases (EN, Eli Lilly)
28.05.24	Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (EN, Eli Lilly)
24.05.24	Lilly Increases Investment In Indiana-Based Unit To Enhance Production Of Zepbound, Mounjaro (RTTNews)
24.05.24	Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines (EN, Eli Lilly)
23.05.24	Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (EN, Eli Lilly)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

29.12.24		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Börse Frankfurt: DAX zum Handelsende auf grünem Terrain
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester
27.12.24		Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
27.12.24		Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge
27.12.24		SLI-Handel aktuell: Zum Handelsende Gewinne im SLI

29.12.24

Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen

27.12.24

Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus

27.12.24

BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester

27.12.24

Börse Frankfurt: DAX zum Handelsende auf grünem Terrain

27.12.24

Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester

27.12.24

Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

27.12.24

Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge

27.12.24

SLI-Handel aktuell: Zum Handelsende Gewinne im SLI

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten